Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07259733
NA

Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)

Sponsor: Instituto Dante Pazzanese de Cardiologia

View on ClinicalTrials.gov

Summary

This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.

Official title: Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

142

Start Date

2023-07-15

Completion Date

2026-12-31

Last Updated

2025-12-02

Healthy Volunteers

No

Interventions

DRUG

Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine)

Participants receive a fixed-dose tablet containing perindopril 10 mg, indapamide 2.5 mg, and amlodipine 10 mg administered once daily for 12 weeks. Randomized participants in this group discontinue their previous antihypertensive medications and replace them with the single-pill triple fixed-dose combination. Treatment adjustments may be made if required according to office blood pressure measurements

DRUG

Usual Care Antihypertensive Regimen

Participants continue their usual antihypertensive therapy, consisting of up to five drug classes administered as separate tablets. Medication types and doses are adjusted by the investigator as needed to achieve office blood pressure control, following standard clinical practice. Treatment modifications are permitted throughout the 12-week study period according to clinical judgment and blood pressure response.

Locations (1)

Instituto Dante Pazzanese de Cardiologia

São Paulo, São Paulo, Brazil